Media stories about OncoSec Medical (NASDAQ:ONCS) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OncoSec Medical earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.127676042592 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
A number of brokerages recently commented on ONCS. HC Wainwright set a $4.00 price target on OncoSec Medical and gave the stock a “buy” rating in a report on Friday, June 29th. Piper Jaffray Companies lifted their price target on OncoSec Medical to $5.00 and gave the stock an “overweight” rating in a report on Tuesday, August 14th. Finally, Dawson James reiterated a “buy” rating on shares of OncoSec Medical in a report on Monday, July 16th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. OncoSec Medical currently has a consensus rating of “Buy” and a consensus price target of $4.67.
OncoSec Medical stock traded up $0.04 during mid-day trading on Friday, reaching $1.53. 36,117 shares of the company’s stock were exchanged, compared to its average volume of 700,972. The firm has a market capitalization of $81.13 million, a P/E ratio of -1.44 and a beta of 2.90. OncoSec Medical has a one year low of $0.90 and a one year high of $2.95.
OncoSec Medical (NASDAQ:ONCS) last issued its quarterly earnings results on Wednesday, June 13th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.04). research analysts anticipate that OncoSec Medical will post -0.84 EPS for the current fiscal year.
In other OncoSec Medical news, Director Avtar S. Dhillon sold 37,575 shares of the business’s stock in a transaction on Thursday, July 5th. The stock was sold at an average price of $1.39, for a total value of $52,229.25. Following the sale, the director now directly owns 181,002 shares in the company, valued at $251,592.78. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Punit Dhillon sold 28,145 shares of the business’s stock in a transaction on Monday, June 18th. The shares were sold at an average price of $1.39, for a total value of $39,121.55. Following the completion of the sale, the director now owns 355,702 shares in the company, valued at $494,425.78. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 300,106 shares of company stock worth $419,658. Corporate insiders own 5.50% of the company’s stock.
About OncoSec Medical
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.
Featured Story: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.